Industry Research Reports

Home > Reports > Chemical & Material > Global Bifidobacterium Infantis Market Outlook, In‑Depth Analysis & Forecast to 2031

Global Bifidobacterium Infantis Market Outlook, In‑Depth Analysis & Forecast to 2031

Industry: Chemical & Material

Published Date: 2025-08-05

Pages: 183 Pages

Report ld: 4855663

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Bifidobacterium Infantis Market Size(US$)

CAGR 2025-2031

6.2%

Market Size,2031

USD 67.7

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 47.2 million

Market Forecast in 2031(Value)

US$ 67.7 million

CAGR

6.2%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Bifidobacterium Infantis market is projected to grow from US$ 44.7 million in 2024 to US$ 67.7 million by 2031, at a CAGR of 6.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.

From a downstream perspective, Food Additives accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Bifidobacterium Infantis leading manufacturers including Mitushi Biopharma, Fengchen Group, Jiangsu Wecare Biotechnology Co., Ltd., Shenzhen Lefu Biotechnology Co., Ltd., Hebei Hongtao Bioengineering Co., Ltd., Shandong Junle Biotechnology Co., Ltd., Shandong Xinxiong Biotechnology Co., Ltd., Newgen Biotech, Pharm-Rx, Rajvi Enterprise, etc., dominate supply; the top five capture approximately % of global revenue, with Mitushi Biopharma leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Bifidobacterium Infantis market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Mitushi Biopharma
Fengchen Group
Jiangsu Wecare Biotechnology Co., Ltd.
Shenzhen Lefu Biotechnology Co., Ltd.
Hebei Hongtao Bioengineering Co., Ltd.
Shandong Junle Biotechnology Co., Ltd.
Shandong Xinxiong Biotechnology Co., Ltd.
Newgen Biotech
Pharm-Rx
Rajvi Enterprise
Shandong Pingao Pharmaceutical Co., Ltd.
Shaanxi Chenming Biotechnology Co., Ltd.
Xi'an Minglang Biotechnology Co., Ltd.
Jiahe Biotechnology (Shanxi) Co., Ltd.
Shaanxi Ruimao Biotechnology Co., Ltd.
Shaanxi Baohe Biotechnology Co., Ltd.
Shaanxi Lesent Biotechnology Co., Ltd.
Shaanxi Shuoyang Biotechnology Co., Ltd.
Shaanxi Mufan Biotechnology Co., Ltd.
Xi'an An'Drong Biomedical Technology Co., Ltd.
Shaanxi Guanchen Biotechnology Co., Ltd.

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

0-50 billion CFU/g
50-100 billion CFU/g
＞100 billion CFU/g

Segment by Application

Food Additives
Medicines and Supplements
Feed Additives
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Bifidobacterium Infantis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.

Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.

Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.

Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.

Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.

Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.

Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.

Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.

Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles

Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.

Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.

Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.

Chapter 15: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:

Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Bifidobacterium Infantis: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Bifidobacterium Infantis Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 0-50 billion CFU/g

1.2.3 50-100 billion CFU/g

1.2.4 ＞100 billion CFU/g

1.3 Market Segmentation by Application

1.3.1 Global Bifidobacterium Infantis Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Food Additives

1.3.3 Medicines and Supplements

1.3.4 Feed Additives

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Bifidobacterium Infantis Revenue Estimates and Forecasts 2020-2031

2.2 Global Bifidobacterium Infantis Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Bifidobacterium Infantis Sales Estimates and Forecasts 2020-2031

2.4 Global Bifidobacterium Infantis Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Global Production Analysis

3.1 Global Bifidobacterium Infantis Production Capacity and Utilization Rates (2020–2031)

3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)

3.3 Regional Production Dynamics

3.3.1 Historic Production by Region (2020-2025)

3.3.2 Forecasted Production by Region (2026-2031)

3.3.3 Production Market Share by Region (2020-2031)

3.3.4 Regulatory and Trade Policy Impact on Production

3.3.5 Production Capacity Enablers and Constraints

3.4 Key Regional Production Hubs

3.4.1 North America

3.4.2 Europe

3.4.3 China

3.4.4 Japan

4 Competition by Manufacturers

4.1 Global Bifidobacterium Infantis Sales by Manufacturers

4.1.1 Global Sales Volume by Manufacturers (2020-2025)

4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

4.2 Global Bifidobacterium Infantis Manufacturer Revenue Rankings and Tiers

4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

4.3 Manufacturer Profitability Profiles and Pricing Strategies

4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

4.3.2 Manufacturer-Level Price Trends (2020-2025)

4.4 Key Manufacturers Manufacturing Base and Headquarters

4.5 Main Product Type Market Size by Manufacturers

4.5.1 0-50 billion CFU/g Market Size by Manufacturers

4.5.2 50-100 billion CFU/g Market Size by Manufacturers

4.5.3 ＞100 billion CFU/g Market Size by Manufacturers

4.6 Global Bifidobacterium Infantis Market Concentration and Dynamics

4.6.1 Global Market Concentration (CR5 and HHI)

4.6.2 Entrant/Exit Impact Analysis

4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

5 Global Product Segmentation Analysis

5.1 Global Bifidobacterium Infantis Sales Performance by Type

5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

5.1.2 Global Sales Market Share by Type (2020-2031)

5.2 Global Bifidobacterium Infantis Revenue Trends by Type

5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

5.2.2 Global Revenue Market Share by Type (2020-2031)

5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

5.4 Product Technology Differentiation

5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

5.5.1 High-Growth Niches and Adoption Drivers

5.5.2 Profitability Hotspots and Cost Drivers

5.5.3 Substitution Threats

6 Global Downstream Application Analysis

6.1 Global Bifidobacterium Infantis Sales by Application

6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

6.1.2 Global Sales Market Share by Application (2020-2031)

6.1.3 High-Growth Application Identification

6.1.4 Emerging Application Case Studies

6.2 Global Bifidobacterium Infantis Revenue by Application

6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

6.2.2 Revenue Market Share by Application (2020-2031)

6.3 Global Pricing Dynamics by Application (2020-2031)

6.4 Downstream Customer Analysis

6.4.1 Top Customers by Region

6.4.2 Top Customers by Application

7 North America

7.1 North America Sales Volume and Revenue (2020-2031)

7.2 North America Key Manufacturers Sales Revenue in 2024

7.3 North America Bifidobacterium Infantis Sales and Revenue by Type (2020-2031)

7.4 North America Bifidobacterium Infantis Sales and Revenue by Application (2020-2031)

7.5 North America Growth Accelerators and Market Barriers

7.6 North America Bifidobacterium Infantis Market Size by Country

7.6.1 North America Revenue by Country

7.6.2 North America Sales Trends by Country

7.6.3 US

7.6.4 Canada

7.6.5 Mexico

8 Europe

8.1 Europe Sales Volume and Revenue (2020-2031)

8.2 Europe Key Manufacturers Sales Revenue in 2024

8.3 Europe Bifidobacterium Infantis Sales and Revenue by Type (2020-2031)

8.4 Europe Bifidobacterium Infantis Sales and Revenue by Application (2020-2031)

8.5 Europe Growth Accelerators and Market Barriers

8.6 Europe Bifidobacterium Infantis Market Size by Country

8.6.1 Europe Revenue by Country

8.6.2 Europe Sales Trends by Country

8.6.3 Germany

8.6.4 France

8.6.5 U.K.

8.6.6 Italy

8.6.7 Russia

9 Asia-Pacific

9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

9.3 Asia-Pacific Bifidobacterium Infantis Sales and Revenue by Type (2020-2031)

9.4 Asia-Pacific Bifidobacterium Infantis Sales and Revenue by Application (2020-2031)

9.5 Asia-Pacific Bifidobacterium Infantis Market Size by Region

9.5.1 Asia-Pacific Revenue by Region

9.5.2 Asia-Pacific Sales Trends by Region

9.6 Asia-Pacific Growth Accelerators and Market Barriers

9.7 Southeast Asia

9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand

9.8 China

9.9 Japan

9.10 South Korea

9.11 China Taiwan

9.12 India

10 Central and South America

10.1 Central and South America Sales Volume and Revenue (2020-2031)

10.2 Central and South America Key Manufacturers Sales Revenue in 2024

10.3 Central and South America Bifidobacterium Infantis Sales and Revenue by Type (2020-2031)

10.4 Central and South America Bifidobacterium Infantis Sales and Revenue by Application (2020-2031)

10.5 Central and South America Investment Opportunities and Key Challenges

10.6 Central and South America Bifidobacterium Infantis Market Size by Country

10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 Brazil

10.6.3 Argentina

11 Middle East and Africa

11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

11.3 Middle East and Africa Bifidobacterium Infantis Sales and Revenue by Type (2020-2031)

11.4 Middle East and Africa Bifidobacterium Infantis Sales and Revenue by Application (2020-2031)

11.5 Middle East and Africa Investment Opportunities and Key Challenges

11.6 Middle East and Africa Bifidobacterium Infantis Market Size by Country

11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

11.6.2 GCC Countries

11.6.3 Turkey

11.6.4 Egypt

11.6.5 South Africa

12 Corporate Profile

12.1 Mitushi Biopharma

12.1.1 Mitushi Biopharma Corporation Information

12.1.2 Mitushi Biopharma Business Overview

12.1.3 Mitushi Biopharma Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.1.4 Mitushi Biopharma Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.1.5 Mitushi Biopharma Bifidobacterium Infantis Sales by Product in 2024

12.1.6 Mitushi Biopharma Bifidobacterium Infantis Sales by Application in 2024

12.1.7 Mitushi Biopharma Bifidobacterium Infantis Sales by Geographic Area in 2024

12.1.8 Mitushi Biopharma Bifidobacterium Infantis SWOT Analysis

12.1.9 Mitushi Biopharma Recent Developments

12.2 Fengchen Group

12.2.1 Fengchen Group Corporation Information

12.2.2 Fengchen Group Business Overview

12.2.3 Fengchen Group Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.2.4 Fengchen Group Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.2.5 Fengchen Group Bifidobacterium Infantis Sales by Product in 2024

12.2.6 Fengchen Group Bifidobacterium Infantis Sales by Application in 2024

12.2.7 Fengchen Group Bifidobacterium Infantis Sales by Geographic Area in 2024

12.2.8 Fengchen Group Bifidobacterium Infantis SWOT Analysis

12.2.9 Fengchen Group Recent Developments

12.3 Jiangsu Wecare Biotechnology Co., Ltd.

12.3.1 Jiangsu Wecare Biotechnology Co., Ltd. Corporation Information

12.3.2 Jiangsu Wecare Biotechnology Co., Ltd. Business Overview

12.3.3 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.3.4 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.3.5 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis Sales by Product in 2024

12.3.6 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis Sales by Application in 2024

12.3.7 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis Sales by Geographic Area in 2024

12.3.8 Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis SWOT Analysis

12.3.9 Jiangsu Wecare Biotechnology Co., Ltd. Recent Developments

12.4 Shenzhen Lefu Biotechnology Co., Ltd.

12.4.1 Shenzhen Lefu Biotechnology Co., Ltd. Corporation Information

12.4.2 Shenzhen Lefu Biotechnology Co., Ltd. Business Overview

12.4.3 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.4.4 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.4.5 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis Sales by Product in 2024

12.4.6 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis Sales by Application in 2024

12.4.7 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis Sales by Geographic Area in 2024

12.4.8 Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis SWOT Analysis

12.4.9 Shenzhen Lefu Biotechnology Co., Ltd. Recent Developments

12.5 Hebei Hongtao Bioengineering Co., Ltd.

12.5.1 Hebei Hongtao Bioengineering Co., Ltd. Corporation Information

12.5.2 Hebei Hongtao Bioengineering Co., Ltd. Business Overview

12.5.3 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.5.4 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.5.5 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis Sales by Product in 2024

12.5.6 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis Sales by Application in 2024

12.5.7 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis Sales by Geographic Area in 2024

12.5.8 Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis SWOT Analysis

12.5.9 Hebei Hongtao Bioengineering Co., Ltd. Recent Developments

12.6 Shandong Junle Biotechnology Co., Ltd.

12.6.1 Shandong Junle Biotechnology Co., Ltd. Corporation Information

12.6.2 Shandong Junle Biotechnology Co., Ltd. Business Overview

12.6.3 Shandong Junle Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.6.4 Shandong Junle Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.6.5 Shandong Junle Biotechnology Co., Ltd. Recent Developments

12.7 Shandong Xinxiong Biotechnology Co., Ltd.

12.7.1 Shandong Xinxiong Biotechnology Co., Ltd. Corporation Information

12.7.2 Shandong Xinxiong Biotechnology Co., Ltd. Business Overview

12.7.3 Shandong Xinxiong Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.7.4 Shandong Xinxiong Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.7.5 Shandong Xinxiong Biotechnology Co., Ltd. Recent Developments

12.8 Newgen Biotech

12.8.1 Newgen Biotech Corporation Information

12.8.2 Newgen Biotech Business Overview

12.8.3 Newgen Biotech Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.8.4 Newgen Biotech Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.8.5 Newgen Biotech Recent Developments

12.9 Pharm-Rx

12.9.1 Pharm-Rx Corporation Information

12.9.2 Pharm-Rx Business Overview

12.9.3 Pharm-Rx Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.9.4 Pharm-Rx Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.9.5 Pharm-Rx Recent Developments

12.10 Rajvi Enterprise

12.10.1 Rajvi Enterprise Corporation Information

12.10.2 Rajvi Enterprise Business Overview

12.10.3 Rajvi Enterprise Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.10.4 Rajvi Enterprise Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.10.5 Rajvi Enterprise Recent Developments

12.11 Shandong Pingao Pharmaceutical Co., Ltd.

12.11.1 Shandong Pingao Pharmaceutical Co., Ltd. Corporation Information

12.11.2 Shandong Pingao Pharmaceutical Co., Ltd. Business Overview

12.11.3 Shandong Pingao Pharmaceutical Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.11.4 Shandong Pingao Pharmaceutical Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.11.5 Shandong Pingao Pharmaceutical Co., Ltd. Recent Developments

12.12 Shaanxi Chenming Biotechnology Co., Ltd.

12.12.1 Shaanxi Chenming Biotechnology Co., Ltd. Corporation Information

12.12.2 Shaanxi Chenming Biotechnology Co., Ltd. Business Overview

12.12.3 Shaanxi Chenming Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.12.4 Shaanxi Chenming Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.12.5 Shaanxi Chenming Biotechnology Co., Ltd. Recent Developments

12.13 Xi'an Minglang Biotechnology Co., Ltd.

12.13.1 Xi'an Minglang Biotechnology Co., Ltd. Corporation Information

12.13.2 Xi'an Minglang Biotechnology Co., Ltd. Business Overview

12.13.3 Xi'an Minglang Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.13.4 Xi'an Minglang Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.13.5 Xi'an Minglang Biotechnology Co., Ltd. Recent Developments

12.14 Jiahe Biotechnology (Shanxi) Co., Ltd.

12.14.1 Jiahe Biotechnology (Shanxi) Co., Ltd. Corporation Information

12.14.2 Jiahe Biotechnology (Shanxi) Co., Ltd. Business Overview

12.14.3 Jiahe Biotechnology (Shanxi) Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.14.4 Jiahe Biotechnology (Shanxi) Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.14.5 Jiahe Biotechnology (Shanxi) Co., Ltd. Recent Developments

12.15 Shaanxi Ruimao Biotechnology Co., Ltd.

12.15.1 Shaanxi Ruimao Biotechnology Co., Ltd. Corporation Information

12.15.2 Shaanxi Ruimao Biotechnology Co., Ltd. Business Overview

12.15.3 Shaanxi Ruimao Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.15.4 Shaanxi Ruimao Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.15.5 Shaanxi Ruimao Biotechnology Co., Ltd. Recent Developments

12.16 Shaanxi Baohe Biotechnology Co., Ltd.

12.16.1 Shaanxi Baohe Biotechnology Co., Ltd. Corporation Information

12.16.2 Shaanxi Baohe Biotechnology Co., Ltd. Business Overview

12.16.3 Shaanxi Baohe Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.16.4 Shaanxi Baohe Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.16.5 Shaanxi Baohe Biotechnology Co., Ltd. Recent Developments

12.17 Shaanxi Lesent Biotechnology Co., Ltd.

12.17.1 Shaanxi Lesent Biotechnology Co., Ltd. Corporation Information

12.17.2 Shaanxi Lesent Biotechnology Co., Ltd. Business Overview

12.17.3 Shaanxi Lesent Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.17.4 Shaanxi Lesent Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.17.5 Shaanxi Lesent Biotechnology Co., Ltd. Recent Developments

12.18 Shaanxi Shuoyang Biotechnology Co., Ltd.

12.18.1 Shaanxi Shuoyang Biotechnology Co., Ltd. Corporation Information

12.18.2 Shaanxi Shuoyang Biotechnology Co., Ltd. Business Overview

12.18.3 Shaanxi Shuoyang Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.18.4 Shaanxi Shuoyang Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.18.5 Shaanxi Shuoyang Biotechnology Co., Ltd. Recent Developments

12.19 Shaanxi Mufan Biotechnology Co., Ltd.

12.19.1 Shaanxi Mufan Biotechnology Co., Ltd. Corporation Information

12.19.2 Shaanxi Mufan Biotechnology Co., Ltd. Business Overview

12.19.3 Shaanxi Mufan Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.19.4 Shaanxi Mufan Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.19.5 Shaanxi Mufan Biotechnology Co., Ltd. Recent Developments

12.20 Xi'an An'Drong Biomedical Technology Co., Ltd.

12.20.1 Xi'an An'Drong Biomedical Technology Co., Ltd. Corporation Information

12.20.2 Xi'an An'Drong Biomedical Technology Co., Ltd. Business Overview

12.20.3 Xi'an An'Drong Biomedical Technology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.20.4 Xi'an An'Drong Biomedical Technology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.20.5 Xi'an An'Drong Biomedical Technology Co., Ltd. Recent Developments

12.21 Shaanxi Guanchen Biotechnology Co., Ltd.

12.21.1 Shaanxi Guanchen Biotechnology Co., Ltd. Corporation Information

12.21.2 Shaanxi Guanchen Biotechnology Co., Ltd. Business Overview

12.21.3 Shaanxi Guanchen Biotechnology Co., Ltd. Bifidobacterium Infantis Product Models, Descriptions and Specifications

12.21.4 Shaanxi Guanchen Biotechnology Co., Ltd. Bifidobacterium Infantis Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.21.5 Shaanxi Guanchen Biotechnology Co., Ltd. Recent Developments

13 Value Chain and Supply-Chain Analysis

13.1 Bifidobacterium Infantis Industry Chain

13.2 Bifidobacterium Infantis Upstream Materials Analysis

13.2.1 Raw Materials

13.2.2 Key Suppliers Market Share & Risk Assessment

13.3 Bifidobacterium Infantis Integrated Production Analysis

13.3.1 Manufacturing Footprint Analysis

13.3.2 Production Technology Overview

13.3.3 Regional Cost Drivers

13.4 Bifidobacterium Infantis Sales Channels and Distribution Networks

13.4.1 Sales Channels

13.4.2 Distributors

14 Bifidobacterium Infantis Market Dynamics

14.1 Industry Trends and Evolution

14.2 Market Growth Drivers and Emerging Opportunities

14.3 Market Challenges, Risks, and Restraints

15 Key Findings in the Global Bifidobacterium Infantis Study

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.1.1 Research Programs/Design

16.1.1.2 Market Size Estimation

16.1.1.3 Market Breakdown and Data Triangulation

16.1.2 Data Source

16.1.2.1 Secondary Sources

16.1.2.2 Primary Sources

16.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Bifidobacterium Infantis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Bifidobacterium Infantis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Bifidobacterium Infantis Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Bifidobacterium Infantis Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Bifidobacterium Infantis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)

Table 7. Global Bifidobacterium Infantis Sales by Region (2020-2025) & (Tons)

Table 8. Global Bifidobacterium Infantis Sales by Region (2026-2031) & (Tons)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Bifidobacterium Infantis Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)

Table 11. Global Bifidobacterium Infantis Production by Region (2020-2025) & (Tons)

Table 12. Global Bifidobacterium Infantis Production by Region (2026-2031) & (Tons)

Table 13. Global Bifidobacterium Infantis Sales by Manufacturers (2020-2025) & (Tons)

Table 14. Global Bifidobacterium Infantis Sales Share by Manufacturers (2020-2025)

Table 15. Global Bifidobacterium Infantis Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 16. Global Bifidobacterium Infantis Revenue Market Share by Manufacturers (2020-2025)

Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 18. Global Bifidobacterium Infantis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bifidobacterium Infantis as of 2024)

Table 19. Global Bifidobacterium Infantis Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 20. Global Bifidobacterium Infantis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)

Table 21. Key Manufacturers Bifidobacterium Infantis Manufacturing Base and Headquarters

Table 22. Global Bifidobacterium Infantis Market Concentration Ratio (CR5 and HHI)

Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 25. Global Bifidobacterium Infantis Sales by Type (2020-2025) & (Tons)

Table 26. Global Bifidobacterium Infantis Sales by Type (2026-2031) & (Tons)

Table 27. Global Bifidobacterium Infantis Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Bifidobacterium Infantis Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Bifidobacterium Infantis ASP by Type (2020-2031) & (US$/Ton)

Table 30. Technical Specifications by Key Product Type

Table 31. Global Bifidobacterium Infantis Sales by Application (2020-2025) & (Tons)

Table 32. Global Bifidobacterium Infantis Sales by Application (2026-2031) & (Tons)

Table 33. Bifidobacterium Infantis High-Growth Sectors Demand CAGR (2024-2031)

Table 34. Global Bifidobacterium Infantis Revenue by Application (2020-2025) & (US$ Million)

Table 35. Global Bifidobacterium Infantis Revenue by Application (2026-2031) & (US$ Million)

Table 36. Global Bifidobacterium Infantis ASP by Application (2020-2031) & (US$/Ton)

Table 37. Top Customers by Region

Table 38. Top Customers by Application

Table 39. North America Bifidobacterium Infantis Growth Accelerators and Market Barriers

Table 40. North America Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 41. North America Bifidobacterium Infantis Sales (Tons) by Country (2020 VS 2024 VS 2031)

Table 42. Europe Bifidobacterium Infantis Growth Accelerators and Market Barriers

Table 43. Europe Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 44. Europe Bifidobacterium Infantis Sales (Tons) by Country (2020 VS 2024 VS 2031)

Table 45. Asia-Pacific Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Asia-Pacific Bifidobacterium Infantis Sales (Tons) by Country (2020 VS 2024 VS 2031)

Table 47. Asia-Pacific Bifidobacterium Infantis Growth Accelerators and Market Barriers

Table 48. Southeast Asia Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 49. Central and South America Bifidobacterium Infantis Investment Opportunities and Key Challenges

Table 50. Central and South America Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 51. Middle East and Africa Bifidobacterium Infantis Investment Opportunities and Key Challenges

Table 52. Middle East and Africa Bifidobacterium Infantis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 53. Mitushi Biopharma Corporation Information

Table 54. Mitushi Biopharma Description and Major Businesses

Table 55. Mitushi Biopharma Product Models, Descriptions and Specifications

Table 56. Mitushi Biopharma Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 57. Mitushi Biopharma Sales Value Proportion by Product in 2024

Table 58. Mitushi Biopharma Sales Value Proportion by Application in 2024

Table 59. Mitushi Biopharma Sales Value Proportion by Geographic Area in 2024

Table 60. Mitushi Biopharma Bifidobacterium Infantis SWOT Analysis

Table 61. Mitushi Biopharma Recent Developments

Table 62. Fengchen Group Corporation Information

Table 63. Fengchen Group Description and Major Businesses

Table 64. Fengchen Group Product Models, Descriptions and Specifications

Table 65. Fengchen Group Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 66. Fengchen Group Sales Value Proportion by Product in 2024

Table 67. Fengchen Group Sales Value Proportion by Application in 2024

Table 68. Fengchen Group Sales Value Proportion by Geographic Area in 2024

Table 69. Fengchen Group Bifidobacterium Infantis SWOT Analysis

Table 70. Fengchen Group Recent Developments

Table 71. Jiangsu Wecare Biotechnology Co., Ltd. Corporation Information

Table 72. Jiangsu Wecare Biotechnology Co., Ltd. Description and Major Businesses

Table 73. Jiangsu Wecare Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 74. Jiangsu Wecare Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 75. Jiangsu Wecare Biotechnology Co., Ltd. Sales Value Proportion by Product in 2024

Table 76. Jiangsu Wecare Biotechnology Co., Ltd. Sales Value Proportion by Application in 2024

Table 77. Jiangsu Wecare Biotechnology Co., Ltd. Sales Value Proportion by Geographic Area in 2024

Table 78. Jiangsu Wecare Biotechnology Co., Ltd. Bifidobacterium Infantis SWOT Analysis

Table 79. Jiangsu Wecare Biotechnology Co., Ltd. Recent Developments

Table 80. Shenzhen Lefu Biotechnology Co., Ltd. Corporation Information

Table 81. Shenzhen Lefu Biotechnology Co., Ltd. Description and Major Businesses

Table 82. Shenzhen Lefu Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 83. Shenzhen Lefu Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 84. Shenzhen Lefu Biotechnology Co., Ltd. Sales Value Proportion by Product in 2024

Table 85. Shenzhen Lefu Biotechnology Co., Ltd. Sales Value Proportion by Application in 2024

Table 86. Shenzhen Lefu Biotechnology Co., Ltd. Sales Value Proportion by Geographic Area in 2024

Table 87. Shenzhen Lefu Biotechnology Co., Ltd. Bifidobacterium Infantis SWOT Analysis

Table 88. Shenzhen Lefu Biotechnology Co., Ltd. Recent Developments

Table 89. Hebei Hongtao Bioengineering Co., Ltd. Corporation Information

Table 90. Hebei Hongtao Bioengineering Co., Ltd. Description and Major Businesses

Table 91. Hebei Hongtao Bioengineering Co., Ltd. Product Models, Descriptions and Specifications

Table 92. Hebei Hongtao Bioengineering Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 93. Hebei Hongtao Bioengineering Co., Ltd. Sales Value Proportion by Product in 2024

Table 94. Hebei Hongtao Bioengineering Co., Ltd. Sales Value Proportion by Application in 2024

Table 95. Hebei Hongtao Bioengineering Co., Ltd. Sales Value Proportion by Geographic Area in 2024

Table 96. Hebei Hongtao Bioengineering Co., Ltd. Bifidobacterium Infantis SWOT Analysis

Table 97. Hebei Hongtao Bioengineering Co., Ltd. Recent Developments

Table 98. Shandong Junle Biotechnology Co., Ltd. Corporation Information

Table 99. Shandong Junle Biotechnology Co., Ltd. Description and Major Businesses

Table 100. Shandong Junle Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 101. Shandong Junle Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 102. Shandong Junle Biotechnology Co., Ltd. Recent Developments

Table 103. Shandong Xinxiong Biotechnology Co., Ltd. Corporation Information

Table 104. Shandong Xinxiong Biotechnology Co., Ltd. Description and Major Businesses

Table 105. Shandong Xinxiong Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 106. Shandong Xinxiong Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 107. Shandong Xinxiong Biotechnology Co., Ltd. Recent Developments

Table 108. Newgen Biotech Corporation Information

Table 109. Newgen Biotech Description and Major Businesses

Table 110. Newgen Biotech Product Models, Descriptions and Specifications

Table 111. Newgen Biotech Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 112. Newgen Biotech Recent Developments

Table 113. Pharm-Rx Corporation Information

Table 114. Pharm-Rx Description and Major Businesses

Table 115. Pharm-Rx Product Models, Descriptions and Specifications

Table 116. Pharm-Rx Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 117. Pharm-Rx Recent Developments

Table 118. Rajvi Enterprise Corporation Information

Table 119. Rajvi Enterprise Description and Major Businesses

Table 120. Rajvi Enterprise Product Models, Descriptions and Specifications

Table 121. Rajvi Enterprise Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 122. Rajvi Enterprise Recent Developments

Table 123. Shandong Pingao Pharmaceutical Co., Ltd. Corporation Information

Table 124. Shandong Pingao Pharmaceutical Co., Ltd. Description and Major Businesses

Table 125. Shandong Pingao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications

Table 126. Shandong Pingao Pharmaceutical Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 127. Shandong Pingao Pharmaceutical Co., Ltd. Recent Developments

Table 128. Shaanxi Chenming Biotechnology Co., Ltd. Corporation Information

Table 129. Shaanxi Chenming Biotechnology Co., Ltd. Description and Major Businesses

Table 130. Shaanxi Chenming Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 131. Shaanxi Chenming Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 132. Shaanxi Chenming Biotechnology Co., Ltd. Recent Developments

Table 133. Xi'an Minglang Biotechnology Co., Ltd. Corporation Information

Table 134. Xi'an Minglang Biotechnology Co., Ltd. Description and Major Businesses

Table 135. Xi'an Minglang Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 136. Xi'an Minglang Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 137. Xi'an Minglang Biotechnology Co., Ltd. Recent Developments

Table 138. Jiahe Biotechnology (Shanxi) Co., Ltd. Corporation Information

Table 139. Jiahe Biotechnology (Shanxi) Co., Ltd. Description and Major Businesses

Table 140. Jiahe Biotechnology (Shanxi) Co., Ltd. Product Models, Descriptions and Specifications

Table 141. Jiahe Biotechnology (Shanxi) Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 142. Jiahe Biotechnology (Shanxi) Co., Ltd. Recent Developments

Table 143. Shaanxi Ruimao Biotechnology Co., Ltd. Corporation Information

Table 144. Shaanxi Ruimao Biotechnology Co., Ltd. Description and Major Businesses

Table 145. Shaanxi Ruimao Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 146. Shaanxi Ruimao Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 147. Shaanxi Ruimao Biotechnology Co., Ltd. Recent Developments

Table 148. Shaanxi Baohe Biotechnology Co., Ltd. Corporation Information

Table 149. Shaanxi Baohe Biotechnology Co., Ltd. Description and Major Businesses

Table 150. Shaanxi Baohe Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 151. Shaanxi Baohe Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 152. Shaanxi Baohe Biotechnology Co., Ltd. Recent Developments

Table 153. Shaanxi Lesent Biotechnology Co., Ltd. Corporation Information

Table 154. Shaanxi Lesent Biotechnology Co., Ltd. Description and Major Businesses

Table 155. Shaanxi Lesent Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 156. Shaanxi Lesent Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 157. Shaanxi Lesent Biotechnology Co., Ltd. Recent Developments

Table 158. Shaanxi Shuoyang Biotechnology Co., Ltd. Corporation Information

Table 159. Shaanxi Shuoyang Biotechnology Co., Ltd. Description and Major Businesses

Table 160. Shaanxi Shuoyang Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 161. Shaanxi Shuoyang Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 162. Shaanxi Shuoyang Biotechnology Co., Ltd. Recent Developments

Table 163. Shaanxi Mufan Biotechnology Co., Ltd. Corporation Information

Table 164. Shaanxi Mufan Biotechnology Co., Ltd. Description and Major Businesses

Table 165. Shaanxi Mufan Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 166. Shaanxi Mufan Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 167. Shaanxi Mufan Biotechnology Co., Ltd. Recent Developments

Table 168. Xi'an An'Drong Biomedical Technology Co., Ltd. Corporation Information

Table 169. Xi'an An'Drong Biomedical Technology Co., Ltd. Description and Major Businesses

Table 170. Xi'an An'Drong Biomedical Technology Co., Ltd. Product Models, Descriptions and Specifications

Table 171. Xi'an An'Drong Biomedical Technology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 172. Xi'an An'Drong Biomedical Technology Co., Ltd. Recent Developments

Table 173. Shaanxi Guanchen Biotechnology Co., Ltd. Corporation Information

Table 174. Shaanxi Guanchen Biotechnology Co., Ltd. Description and Major Businesses

Table 175. Shaanxi Guanchen Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 176. Shaanxi Guanchen Biotechnology Co., Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 177. Shaanxi Guanchen Biotechnology Co., Ltd. Recent Developments

Table 178. Key Raw Materials Distribution

Table 179. Raw Materials Key Suppliers

Table 180. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 181. Milestones in Production Technology Evolution

Table 182. Distributors List

Table 183. Market Trends and Market Evolution

Table 184. Market Drivers and Opportunities

Table 185. Market Challenges, Risks, and Restraints

Table 186. Research Programs/Design for This Report

Table 187. Key Data Information from Secondary Sources

Table 188. Key Data Information from Primary Sources

List of Figures

Figure 1. Bifidobacterium Infantis Product Picture

Figure 2. Global Bifidobacterium Infantis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. 0-50 billion CFU/g Product Picture

Figure 4. 50-100 billion CFU/g Product Picture

Figure 5. ＞100 billion CFU/g Product Picture

Figure 6. Global Bifidobacterium Infantis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Food Additives

Figure 8. Medicines and Supplements

Figure 9. Feed Additives

Figure 10. Others

Figure 11. Bifidobacterium Infantis Report Years Considered

Figure 12. Global Bifidobacterium Infantis Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 14. Global Bifidobacterium Infantis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global Bifidobacterium Infantis Revenue Market Share by Region (2020-2031)

Figure 16. Global Bifidobacterium Infantis Sales (2020-2031) & (Tons)

Figure 17. Global Bifidobacterium Infantis Sales (CAGR) by Region (2020-2031) (Tons)

Figure 18. Global Bifidobacterium Infantis Sales Market Share by Region (2020-2031)

Figure 19. Global Bifidobacterium Infantis Capacity, Production and Utilization (2020-2031) & (Tons)

Figure 20. Global Bifidobacterium Infantis Production Trend by Region (2020-2031) (Tons)

Figure 21. Global Bifidobacterium Infantis Production Market Share by Region (2020-2031)

Figure 22. Production Capacity Enablers & Constraints

Figure 23. Bifidobacterium Infantis Production Growth Rate in North America (2020-2031) & (Tons)

Figure 24. Bifidobacterium Infantis Production Growth Rate in Europe (2020-2031) & (Tons)

Figure 25. Bifidobacterium Infantis Production Growth Rate in China (2020-2031) & (Tons)

Figure 26. Bifidobacterium Infantis Production Growth Rate in Japan (2020-2031) & (Tons)

Figure 27. Top 5 and Top 10 Manufacturers Bifidobacterium Infantis Sales Volume Market Share in 2024

Figure 28. Global Bifidobacterium Infantis Revenue Market Share Ranking (2024)

Figure 29. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 30. 0-50 billion CFU/g Revenue Market Share by Manufacturer in 2024

Figure 31. 50-100 billion CFU/g Revenue Market Share by Manufacturer in 2024

Figure 32. ＞100 billion CFU/g Revenue Market Share by Manufacturer in 2024

Figure 33. Type Eight Revenue Market Share by Manufacturer in 2024

Figure 34. Type Nine Revenue Market Share by Manufacturer in 2024

Figure 35. Global Bifidobacterium Infantis Sales Market Share by Type (2020-2031)

Figure 36. Global Bifidobacterium Infantis Revenue Market Share by Type (2020-2031)

Figure 37. Global Bifidobacterium Infantis Sales Market Share by Application (2020-2031)

Figure 38. Global Bifidobacterium Infantis Revenue Market Share by Application (2020-2031)

Figure 39. North America Bifidobacterium Infantis Sales YoY (2020-2031) & (Tons)

Figure 40. North America Bifidobacterium Infantis Revenue YoY (2020-2031) & (US$ Million)

Figure 41. North America Top 5 Manufacturers Bifidobacterium Infantis Sales Revenue (US$ Million) in 2024

Figure 42. North America Bifidobacterium Infantis Sales Volume (Tons) by Type (2020- 2031)

Figure 43. North America Bifidobacterium Infantis Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 44. North America Bifidobacterium Infantis Sales Volume (Tons) by Application (2020-2031)

Figure 45. North America Bifidobacterium Infantis Sales Revenue (US$ Million) by Application (2020-2031)

Figure 46. US Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 47. Canada Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 48. Mexico Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 49. Europe Bifidobacterium Infantis Sales YoY (2020-2031) & (Tons)

Figure 50. Europe Bifidobacterium Infantis Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Europe Top 5 Manufacturers Bifidobacterium Infantis Sales Revenue (US$ Million) in 2024

Figure 52. Europe Bifidobacterium Infantis Sales Volume (Tons) by Type (2020-2031)

Figure 53. Europe Bifidobacterium Infantis Sales Revenue (US$ Million) by Type (2020-2031)

Figure 54. Europe Bifidobacterium Infantis Sales Volume (Tons) by Application (2020-2031)

Figure 55. Europe Bifidobacterium Infantis Sales Revenue (US$ Million) by Application (2020-2031)

Figure 56. Germany Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 57. France Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 58. U.K. Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 59. Italy Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 60. Russia Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 61. Asia-Pacific Bifidobacterium Infantis Sales YoY (2020-2031) & (Tons)

Figure 62. Asia-Pacific Bifidobacterium Infantis Revenue YoY (2020-2031) & (US$ Million)

Figure 63. Asia-Pacific Top 8 Manufacturers Bifidobacterium Infantis Sales Revenue (US$ Million) in 2024

Figure 64. Asia-Pacific Bifidobacterium Infantis Sales Volume (Tons) by Type (2020- 2031)

Figure 65. Asia-Pacific Bifidobacterium Infantis Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 66. Asia-Pacific Bifidobacterium Infantis Sales Volume (Tons) by Application (2020-2031)

Figure 67. Asia-Pacific Bifidobacterium Infantis Sales Revenue (US$ Million) by Application (2020-2031)

Figure 68. Indonesia Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 69. Japan Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 70. South Korea Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 71. China Taiwan Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 72. India Bifidobacterium Infantis Revenue (2020-2031) & (US$ Million)

Figure 73. Central and South America Bifidobacterium Infantis Sales YoY (2020-2031) & (Tons)

Figure 74. Central and South America Bifidobacterium Infantis Revenue YoY (2020-2031) & (US$ Million)

Figure 75. Central and South America Top 5 Manufacturers Bifidobacterium Infantis Sales Revenue (US$ Million) in 2024

Figure 76. Central and South America Bifidobacterium Infantis Sales Volume (Tons) by Type (2021-2031)

Figure 77. Central and South America Bifidobacterium Infantis Sales Revenue (US$ Million) by Type (2020-2031)

Figure 78. Central and South America Bifidobacterium Infantis Sales Volume (Tons) by Application (2020-2031)

Figure 79. Central and South America Bifidobacterium Infantis Sales Revenue (US$ Million) by Application (2020-2031)

Figure 80. Brazil Bifidobacterium Infantis Revenue (2020-2025) & (US$ Million)

Figure 81. Argentina Bifidobacterium Infantis Revenue (2020-2025) & (US$ Million)

Figure 82. Middle East, and Africa Bifidobacterium Infantis Sales YoY (2020-2031) & (Tons)

Figure 83. Middle East and Africa Bifidobacterium Infantis Revenue YoY (2020-2031) & (US$ Million)

Figure 84. Middle East and Africa Top 5 Manufacturers Bifidobacterium Infantis Sales Revenue (US$ Million) in 2024

Figure 85. Middle East and Africa Bifidobacterium Infantis Sales Volume (Tons) by Type (2021-2031)

Figure 86. South America Bifidobacterium Infantis Sales Revenue (US$ Million) by Type (2020-2031)

Figure 87. Middle East and Africa Bifidobacterium Infantis Sales Volume (Tons) by Application (2020-2031)

Figure 88. Middle East and Africa Bifidobacterium Infantis Sales Revenue (US$ Million) by Application (2020-2031)

Figure 89. GCC Countries Bifidobacterium Infantis Revenue (2020-2025) & (US$ Million)

Figure 90. Turkey Bifidobacterium Infantis Revenue (2020-2025) & (US$ Million)

Figure 91. Egypt Bifidobacterium Infantis Revenue (2020-2025) & (US$ Million)

Figure 92. South Africa Bifidobacterium Infantis Revenue (2020-2025) & (US$ Million)

Figure 93. Bifidobacterium Infantis Industry Chain Mapping

Figure 94. Regional Bifidobacterium Infantis Manufacturing Base Distribution (%)

Figure 95. Bifidobacterium Infantis Production Process

Figure 96. Regional Bifidobacterium Infantis Production Cost Structure

Figure 97. Channels of Distribution (Direct Vs Distribution)

Figure 98. Bottom-up and Top-down Approaches for This Report

Figure 99. Data Triangulation

Figure 100. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Bifidobacterium Infantis market size from 2025 to 2031? zhanKai

The annual compound growth rate of the global Bifidobacterium Infantis market is 6.2% 2025 to 2031.

Which region is expected to have the highest market share? shouQi

What was the global market size of Bifidobacterium Infantis in 2025? shouQi

Which companies rank high in the global Bifidobacterium Infantis market? shouQi

What was the global market size of Bifidobacterium Infantis in 2031? shouQi

Related Reports

Global Bifidobacterium Infantis Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Bifidobacterium Infantis market is projected to grow from US$ 47.19 million in 2025 to US$ 71.49 million by 2032, at a CAGR of 6.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-26
Pages: 182
USD 4900.00
(Single User License)
Global Bifidobacterium Infantis Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Bifidobacterium Infantis market size was US$ 47.19 million in 2025 and is forecast to reach a readjusted size of US$ 71.49 million by 2032 with a CAGR of 6.2% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 120
USD 4250.00
(Single User License)
Bifidobacterium Infantis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Bifidobacterium Infantis was estimated to be worth US$ 47.19 million in 2025 and is projected to reach US$ 71.49 million, growing at a CAGR of 6.2% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 169
USD 3950.00
(Single User License)
Global Bifidobacterium Infantis Market Research Report 2026
The global Bifidobacterium Infantis market was valued at US$ 47.19 million in 2025 and is anticipated to reach US$ 71.49 million by 2032, at a CAGR of 6.2% from 2026 to 2032.
Published Date: 2026-01-09
Pages: 156
USD 2900.00
(Single User License)
Global Bifidobacterium Infantis Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Bifidobacterium Infantis market size was US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published Date: 2025-03-10
Pages: 119
USD 4250.00
(Single User License)
Bifidobacterium Infantis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Bifidobacterium Infantis was estimated to be worth US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published Date: 2025-03-10
Pages: 162
USD 3950.00
(Single User License)
Global Bifidobacterium Infantis Market Research Report 2025
The global market for Bifidobacterium Infantis was valued at US$ 44.7 million in the year 2024 and is projected to reach a revised size of US$ 67.7 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Published Date: 2025-03-10
Pages: 118
USD 2900.00
(Single User License)
Global and United States Bifidobacterium Infantis Market Report & Forecast 2024-2030
Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published Date: 2024-09-11
Pages: 171
USD 4350.00
(Single User License)
Global Bifidobacterium Infantis Market Research Report 2024
Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published Date: 2024-09-11
Pages: 124
USD 2900.00
(Single User License)
Global Bifidobacterium Infantis Market Insights, Forecast to 2030
Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published Date: 2024-09-11
Pages: 191
USD 4900.00
(Single User License)

Global Bifidobacterium Infantis Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Bifidobacterium Infantis market is projected to grow from US$ 47.19 million in 2025 to US$ 71.49 million by 2032, at a CAGR of 6.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-26
Pages: 182
USD 4900.00 (Single User License)
Global Bifidobacterium Infantis Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Bifidobacterium Infantis market size was US$ 47.19 million in 2025 and is forecast to reach a readjusted size of US$ 71.49 million by 2032 with a CAGR of 6.2% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 120
USD 4250.00 (Single User License)
Bifidobacterium Infantis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Bifidobacterium Infantis was estimated to be worth US$ 47.19 million in 2025 and is projected to reach US$ 71.49 million, growing at a CAGR of 6.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 169
USD 3950.00 (Single User License)
Global Bifidobacterium Infantis Market Research Report 2026
The global Bifidobacterium Infantis market was valued at US$ 47.19 million in 2025 and is anticipated to reach US$ 71.49 million by 2032, at a CAGR of 6.2% from 2026 to 2032.
Published: 2026-01-09
Pages: 156
USD 2900.00 (Single User License)
Global Bifidobacterium Infantis Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Bifidobacterium Infantis market size was US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published: 2025-03-10
Pages: 119
USD 4250.00 (Single User License)
Bifidobacterium Infantis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Bifidobacterium Infantis was estimated to be worth US$ 44.7 million in 2024 and is forecast to a readjusted size of US$ 67.7 million by 2031 with a CAGR of 6.2% during the forecast period 2025-2031.
Published: 2025-03-10
Pages: 162
USD 3950.00 (Single User License)
Global Bifidobacterium Infantis Market Research Report 2025
The global market for Bifidobacterium Infantis was valued at US$ 44.7 million in the year 2024 and is projected to reach a revised size of US$ 67.7 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Published: 2025-03-10
Pages: 118
USD 2900.00 (Single User License)
Global and United States Bifidobacterium Infantis Market Report & Forecast 2024-2030
Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published: 2024-09-11
Pages: 171
USD 4350.00 (Single User License)
Global Bifidobacterium Infantis Market Research Report 2024
Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published: 2024-09-11
Pages: 124
USD 2900.00 (Single User License)
Global Bifidobacterium Infantis Market Insights, Forecast to 2030
Bifidobacterium Infantis is a subspecies of Bifidobacterium longum infantis that mainly inhabits the intestines of human infants. Clinical studies have shown that it has a strong ability to utilize human milk oligosaccharides (HMO) contained in breast milk, which can improve the intestinal environment of healthy infants and young children. It is also known as the probiotic of the new era of HMO.
Published: 2024-09-11
Pages: 191
USD 4900.00 (Single User License)